ライフサイエンスコーパス: residual risk

1 rapy, Lp(a) was a significant determinant of residual risk.

2 novel therapies are required to reduce this residual risk.

3 C, apolipoprotein B, or ratios in predicting residual risk.

4 redictor of incident events and biomarker of residual risk.

5 allow better estimation of carrier rates and residual risks.

6 goal of this study was to determine whether residual risk after high-dose statin therapy for primary

7 r particle number (HDL-P) as determinants of residual risk after potent statin therapy.

8 tic techniques enables the estimation of the residual risk after the consumption of a product that un

9 The overall residual risk and the risk associated with these measure

10 Understanding of residual risk, anxiety levels, and overall satisfaction

11 erol with statins, there remains significant residual risk as evidenced by incident and recurrent car

12 d abnormal lipids, ideal treatment goals and residual risk, as well as statin potency.

13 The residual risk at guideline-recommended targets was estim

14 screening panels, they recommend to compute residual risk based on ethnicity.

15 The residual risk conferred by low HDL-C in patients with a

16 lipoproteins (TRLs) represents an important residual risk factor for cardiovascular and chronic kidn

17 Residual risk factors are associated with the likelihood

18 ency, PIK3CA mutations do not seem to affect residual risk following treatment with endocrine therapy

19 LDL-C as the primary target of therapy, yet residual risk for cardiovascular disease (CVD) among sta

20 pective on some of these salient issues: the residual risk for disease progression after sustained vi

21 tor-positive breast cancer have considerable residual risk for recurrence after completing 5 years of

22 lity that HDL modification could address the residual risk has brought renewed focus on an old HDL-ra

23 The pursuit of novel therapies to target the residual risk has focused on raising the levels of high-

24 Risk factors for this "residual risk" have not been studied comprehensively.

25 it is associated with a progressively higher residual risk, ie, higher treatment failures.

26 festyle counseling more effective; assessing residual risk in a treated patient; diagnosing and treat

27 Determinants of residual risk in statin-treated secondary prevention pat

28 res help to identify patients at the highest residual risk in the present era.

29 is unknown whether Lp(a) is a determinant of residual risk in the setting of low low-density lipoprot

30 Estimated viral residual risks increased slightly after the attacks (HIV

31 States, there is a need to better integrate residual risk into cardiovascular disease (CVD) risk str

32 progression of diabetic kidney disease, the residual risk is high.

33 Residual risk is related to residual albuminuria.

34 candidate genes that may contribute to this residual risk is the endothelial nitric oxide synthase (

35 Lp(a) levels, possibly contributing to the "residual risk" noted in outcomes trials and at the bedsi

36 in Lp(a) concentrations were associated with residual risk of cardiovascular disease (adjusted hazard

37 ognised in nephrology, could help to explain residual risk of cardiovascular events in the general po

38 eutic strategies, there remains an extensive residual risk of clinical events, particularly in high-r

39 ant associations of a similar magnitude with residual risk of CVD were found for on-treatment LDL-C,

40 d atherogenic particles were associated with residual risk of CVD/all-cause death.

41 s; change in population-level incidence; and residual risk of Kaposi's sarcoma.

42 n and may account, at least in part, for the residual risk of lung cancer among former smokers.

43 This study aimed to analyze the residual risk of MI, together with relevant associated f

44 ovascular treatment goals is associated with residual risk of mortality and cardiovascular outcomes i

45 We observed that the residual risk of recurrence was higher in breast cancer

46 er women treated with warfarin have a higher residual risk of stroke in comparison with men.

47 thogen-reduction technologies to address the residual risk of TAS as well as the potential risk of th

48 HCV infections annually and has reduced the residual risk of transfusion-transmitted HIV-1 and HCV t

49 Treatment of the residual risk, other than blood pressure and LDL-cholest

50 Residual risk persists despite statin therapy and additi

51 As a result, carrier rates and residual risks provided for patient decision-making are

52 explained by health behaviors, although some residual risk remained unexplained.

53 Nonetheless, residual risk remains high, and statin intolerance is fr

54 ite statin treatment, cardiovascular disease residual risk remains high.

55 scular events by about 25-35%, a substantial residual risk remains, leading to a search for additiona

56 et levels of LDL-C, and thus, LDL-associated residual risk remains.

57 DL particle number may be a better marker of residual risk than chemically measured HDL-C or apoA-I.

58 o estimated the potential risk reduction and residual risk that can be achieved if patients reach gui